{"id":21467,"date":"2023-03-03T23:44:00","date_gmt":"2023-03-03T15:44:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21467"},"modified":"2025-01-13T23:47:15","modified_gmt":"2025-01-13T15:47:15","slug":"nhc-recommends-simcere-and-junshi-covid-19-therapies-in-updated-guidelines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21467","title":{"rendered":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines"},"content":{"rendered":"\n<p>The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences\u2019 (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms within the first 3 days of mild and moderate COVID-19 cases. The therapies were conditionally approved for marketing in China on January 19, marking a significant step in the country&#8217;s response to the pandemic.<\/p>\n\n\n\n<p><strong>Therapies and Recommendations<\/strong><br>SIM0417 and JT001 (VV116) have been included in the NHC&#8217;s updated treatment guidelines, reflecting their potential effectiveness in managing COVID-19 symptoms. The recommendation to use these therapies within the first 3 days of symptom onset in mild and moderate cases highlights their importance in the early intervention and management of the disease. This approach aims to reduce the severity of the illness and improve patient outcomes.<\/p>\n\n\n\n<p><strong>Conditional Approval and Market Access<\/strong><br>The conditional approval of SIM0417 and JT001 (VV116) for marketing in China is a testament to the rapid development and regulatory response to the pandemic. This approval allows for the broader use of these therapies in clinical settings, providing healthcare providers with additional tools to combat COVID-19. The inclusion in the NHC&#8217;s treatment plan further validates their potential role in the ongoing fight against the virus.<\/p>\n\n\n\n<p><strong>Future Prospects<\/strong><br>The inclusion of Simcere and Junshi&#8217;s therapies in the NHC&#8217;s guidelines is a significant development in China&#8217;s COVID-19 treatment strategy. As the pandemic continues to evolve, the availability of effective treatments remains crucial. SIM0417 and JT001 (VV116) offer new options for healthcare providers, potentially improving patient care and contributing to the global effort to control and treat COVID-19.<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (HKG: 2096)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[13,899,1099,296,900,271],"class_list":["post-21467","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-covid-19","tag-hkg-1877","tag-hkg-2096","tag-junshi-biosciences","tag-sha-688180","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences\u2019 (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms within the first 3 days of mild and moderate COVID-19 cases. The therapies were conditionally approved for marketing in China on January 19, marking a significant step in the country&#039;s response to the pandemic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21467\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21467\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-03T15:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T15:47:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines\",\"datePublished\":\"2023-03-03T15:44:00+00:00\",\"dateModified\":\"2025-01-13T15:47:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467\"},\"wordCount\":299,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"COVID-19\",\"HKG: 1877\",\"HKG: 2096\",\"Junshi Biosciences\",\"SHA: 688180\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21467#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21467\",\"name\":\"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-03T15:44:00+00:00\",\"dateModified\":\"2025-01-13T15:47:15+00:00\",\"description\":\"The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences\u2019 (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms within the first 3 days of mild and moderate COVID-19 cases. The therapies were conditionally approved for marketing in China on January 19, marking a significant step in the country's response to the pandemic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21467\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21467#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines - Insight, China&#039;s Pharmaceutical Industry","description":"The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences\u2019 (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms within the first 3 days of mild and moderate COVID-19 cases. The therapies were conditionally approved for marketing in China on January 19, marking a significant step in the country's response to the pandemic.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21467","og_locale":"en_US","og_type":"article","og_title":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21467","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-03T15:44:00+00:00","article_modified_time":"2025-01-13T15:47:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21467#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21467"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines","datePublished":"2023-03-03T15:44:00+00:00","dateModified":"2025-01-13T15:47:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21467"},"wordCount":299,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["COVID-19","HKG: 1877","HKG: 2096","Junshi Biosciences","SHA: 688180","Simcere Pharmaceutical"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21467#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21467","url":"https:\/\/flcube.com\/?p=21467","name":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-03T15:44:00+00:00","dateModified":"2025-01-13T15:47:15+00:00","description":"The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group\u2019s (HKG: 2096) small-molecule COVID-19 therapy SIM0417 and Junshi Biosciences\u2019 (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) in the 10th version of the COVID-19 Diagnosis and Treatment Plan. Both drugs are recommended for the treatment of symptoms within the first 3 days of mild and moderate COVID-19 cases. The therapies were conditionally approved for marketing in China on January 19, marking a significant step in the country's response to the pandemic.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21467#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21467"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21467#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21467"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21467\/revisions"}],"predecessor-version":[{"id":21468,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21467\/revisions\/21468"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}